143 related articles for article (PubMed ID: 15603261)
1. [The rise and fall of Vioxx: society, values and their choice].
Caspi D
Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
[No Abstract] [Full Text] [Related]
2. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
3. [Really only Vioxx?].
Heinzl S
Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
[No Abstract] [Full Text] [Related]
4. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
5. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
6. Health Canada lukewarm on Vioxx panel findings.
Murray S
CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
[No Abstract] [Full Text] [Related]
7. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
8. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
Jerie P
Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
[No Abstract] [Full Text] [Related]
9. New use approved for Vioxx.
FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
[No Abstract] [Full Text] [Related]
10. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
[No Abstract] [Full Text] [Related]
11. Will Merck survive Vioxx?
Simons J; Stipp D
Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
[No Abstract] [Full Text] [Related]
12. Merck withdraws Vioxx; FDA issues public health advisory.
FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
[No Abstract] [Full Text] [Related]
13. The Vioxx debacle revisited.
Manthous CA
Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
[No Abstract] [Full Text] [Related]
14. What happened to the coxibs on the way to the cardiologist?
Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
[No Abstract] [Full Text] [Related]
15. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
16. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
17. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
18. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
19. COX-2 inhibitors and hypercoagulability.
Farkouh ME
Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
[No Abstract] [Full Text] [Related]
20. Discontinuation of Vioxx.
Nutt DJ
Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
[No Abstract] [Full Text] [Related]
[Next] [New Search]